GlassScriptPhysician profile
Renee L Cevey
NPI 1770561458
$2,340.30
in general payments reported to CMS, 2019-2025
24 companies · $262 in 2025
The $262 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $225 · 2021: $352 · 2022: $300 · 2023: $415 · 2024: $555 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $322.99 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Sanofi Pasteur INC. | $299.50 | 2021-2024 | |
| Pfizer INC. | $296.64 | 2020-2024 | |
| Corium, LLC | $249.33 | 2023-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $185.01 | 2019-2021 | |
| Glaxosmithkline, LLC. | $139.25 | 2025 | Penmenvy, Pediarix, Rotarix |
| Tris Pharma INC | $138.96 | 2019-2022 | |
| Cranial Technologies, INC | $123.69 | 2021-2025 | Doc Band |
| Alk-Abello, INC | $105.92 | 2024-2025 | Grastek, Odactra, Ragwitek |
| Ironshore Pharmaceuticals INC. | $96.28 | 2019-2024 | |
| Arbor Pharmaceuticals, INC. | $56.63 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $50.51 | 2023-2025 | Flumist Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $39.24 | 2020-2022 | |
| Seqirus USA INC | $34.99 | 2021-2024 | Flucelvax |
| Kaleo, INC. | $32.90 | 2022-2023 | Auvi-Q |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $31.88 | 2019 | |
| Aytu Biopharma, INC. | $23.08 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $21.19 | 2024 | Qelbree |
| Collegium Pharmaceutical, INC. | $17.10 | 2025 | Jornay Pm |
| Shire North American Group INC | $16.48 | 2019 | |
| Organon LLC | $15.46 | 2025 | |
| Vertical Pharmaceuticals, LLC | $15.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.59 | 2019 | |
| Verrica Pharmaceuticals INC. | $13.66 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Cevey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.